tbuckley/cabot-search huggingface dataset:
A pilot study of trans arterial chemo-embolization (TACE) with drug eluting beads irinotecan (IRI) preloaded (DEBI) for liver metastases (LM) from uveal melanoma (UM): An Italian National Study
Authors: G. Fiorentini, C. Aliberti, G. Benea, M. Tilli, A. Del Conte
Journal: Journal of Clinical Oncology (2008)

20010 Background: Exclusive LM occur in up to 40% of patients with UM associated with a median survival of 2–5 months; surgery and chemotherapy have poor results. Experimental efficacy of IRI on B16 melanoma cells was reported and studies with oral IRI showed interesting activity in melanoma patients. TACE seems effective in palliation of LM from different tumours. Methods: Between February 2006 and November 2007, nine patients with LM from UM (F/M = 4/5, median age 44 yrs, liver replacement (LR) 25% = 2 cases, 50% = 2 cases, 75% = 5), treated with surgery (3 cases) and chemo-immunotherapy (9) were enrolled into a pilot trial of TACE with DEBI. One patient had early death and two had early progression during staging and were not treated. TACE with DEBI (adopting beads with diameter of 300–500 μ in the first triplet of patients and 100–300 μ in the second triplet) preloaded with 200 mg of IRI was delivered every 4 weeks for 2 folds. Computed Tomography was performed 24h before and after treatment, then every month till progression. Before treatment intra-arterial lidocaine and from day 0 to 4 analgesic medications, antibiotics and intravenously hydration were administered Results: Six patients received 12 cycles (2 each patient). Right upper quadrant pain (RUQP) grade 2 short lasting, fever grade 2 lasting 3 days (range 2–7) and increases of liver enzymes grade 2–3 were reported by all patients. After 30 days, a reduction of 75% of the lesional contrast enhancement was observed in the first triplet of patients. A complete disappearance of enhancement was observed in the second triplet. Three patients with LR = 75% died at 64 days, 120, 155. Two patients with LR = 25% are alive at 188 and 431 days respectively. One with LR = 50% is alive at 147 days Conclusions: TACE with DEBI is feasible and safe in patients with LM from UM. Fever, RUQP, increases of liver enzymes are the side effects. Responses seem related to beads diameter. Survival is related to liver substitution. No significant financial relationships to disclose.
Anaphylaxis and Sensitisation. With Special Reference to the Skin and Its Diseases.
Authors: Robert Cranston Low
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Handbook of Clinical Pathology.
Authors: Julie Sandstad, Robert McKenna, Joseph H. Keffer
Journal: Annals of Internal Medicine (1929)

This handbook provides complete and practical information on appropriate laboratory test selection and interpretation. A supplement for medical students during their second year pathology course and a valuable aid for pathology residents, pathologists and medical technologists, the book features 45 quick-reference tables, concise discussions, and extensive references. Coverage includes clinical cytogenetics; infectious disease tests; pregnancy tests; tumor biomarkers; laboratory tests for myocardial injury; plasma lipoproteins; cerebrospinal and synovial fluids; connective tissue disease tests; gastrointestinal, renal and endocrine function tests; urinalysis; calcium and phosphorus metabolism; leukocyte and erythrocyte disorders and practical hematology.
Prevasculrization using gelatin microsphere containing basic-fibroblast growth factor enhances the benefits of cardiomyocytes transplantation in rats with ischemic cardiomyopathy.
Authors: Y Sakakibara, M Yamamoto, K Nishimura, T Nishina, S Miwa, N Handa, T Nomoto, K Tanbara, Y Tabata, M Komeda
Journal: Circulation (2000)
Governmental Provisions in the United States and Foreign Countries for Members of the Military Forces and Their Dependents.
Authors: S. Herbert Wolfe
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Our Children: A Handbook for Parents.
Authors: Sidonie Matsner Gruenberg, Dorothy Canfield Fisher
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gluten-sensitive Enteropathy
Authors: Z. M. Falchuk, D. L. Nelson, A. J. Katz, J. E. Bernardin, D. D. Kasarda, N. E. Hague, W. Strober
Journal: Journal of Clinical Investigation (1980)

We previously developed an in vitro organ culture system in which gluten exerts a toxic effect on intestinal mucosa of patients with active gluten-sensitive enteropathy. Gluten generally inhibits the epithelial cell maturation of intestinal biopsy specimens that otherwise occurs if the tissue is cultured for 24-48 h in a gluten-free medium. However, small intestinal mucosa from 15-20% of patients with proven gluten-sensitive enteropathy fails to manifest the expected gluten-induced damage in vitro. In the present study, we explored the relation between in vitro gluten-induced intestinal damage and the presence of HLA-B8. We determined whether the patients' histocompatibility type (HLA-B8 positive or negative) influenced the ability of gluten protein to inhibit epithelial cell maturation of cultured intestinal biopsy specimens from patients with gluten-sensitive enteropathy.
Synchronous and metachronous bilateral breast cancer: Are the risks greater in women with a history of radiation for Hodgkin lymphoma?
Authors: E. B. Elkin, A. R. Gonzales, N. M. Ishill, M. L. Klem, D. Hodgson, A. K. Ng, L. B. Marks, J. Weidhaas, G. M. Freedman, R. C. Miller, J. Yahalom
Journal: Journal of Clinical Oncology (2009)

607 Background: Women with a history of radiation therapy (RT) for Hodgkin lymphoma (HL) have an elevated risk of breast cancer (BC). The characteristics, treatment and outcomes of these cancers, compared with sporadic breast cancers, are not well described. In particular, rates of synchronous and metachronous bilateral BC may be greater in patients with a history of RT for HL. Methods: Women diagnosed with BC between 1980 and 2006 following RT for HL were identified retrospectively from 8 institutions in North America. Each patient in this cohort was matched with 3 BC patients with no history of HL, from the same institution, by age at BC diagnosis, year of BC diagnosis and race. Information on patient and tumor characteristics, disease recurrence and new contralateral tumors was obtained from medical records. Analysis of metachronous contralateral breast cancer (CBC) was limited to women with a breast at risk, and adjusted hazard ratios (HRs) for CBC were estimated using Cox proportional hazards regression. Results: 253 BC patients with a history of RT for HL were matched with 741 patients with sporadic BC. The median interval between HL and first BC diagnosis was 19 years. Median age at BC diagnosis was 44 years and median follow-up was 5 years from BC diagnosis. Synchronous bilateral BC was diagnosed in 6% of the HL survivors and 2% of the matched patients with sporadic BC. Among women with unilateral disease, 21% of HL survivors and 3% of sporadic BC patients had a bilateral mastectomy. Overall 64 women with a breast at risk developed metachronous CBC. BC patients with a history of RT for HL had a greater rate of metachronous CBC (adjusted hazard ratio 3.3, 95% CI 2.1–5.8), controlling for patient, tumor and treatment characteristics. In addition, those who received chemotherapy for BC were less likely to develop CBC (adjusted HR 0.51, 95% CI 0.31–0.85), and those with a family history of BC in a 1 st degree relative were more likely to develop CBC (adjusted HR 1.8, 95% CI 1.1–3.0). Conclusions: Women who develop BC after RT for HL have more than 3 times the risk of CBC than similar women with sporadic BC. Our findings support close follow-up for CBC in BC patients with a history of RT for HL and may inform decisions about prophylactic mastectomy in this population. No significant financial relationships to disclose.
Abstract 20128: Adiponectin Upregulation in Epicardial Fat Ameliorates Ischemia- Induced Cardiac Dysfunction in Obese Rats Through Recruitment of LKB1 and pAMPK.
Authors: Stephen J Peterson, Jian Cao, Luca Vanella, Kazuyoski Inoue, Komal Sodhi, Rita Rezzani, Luigi F Rodella, Antonio L'Abbate, Nader G Abraham
Journal: Circulation (2010)

High Fat (HF) diets increase cardiovascular risk presumably by a decrease in the redox state, radical scavenging activities and decreased adiponectin release in epicardial fat. Adiponectin plays a ...
Law in the Practice of Psychiatry. A Handbook for Clinicians.
Authors: Seymour L. Halleck
Journal: Annals of Internal Medicine (1981)

Introduction: Psychiatry and Law-General Issues.- I Malpractice.- 1 Medical Malpractice Law and the Psychiatrist.- 2 Intentional Torts in Psychiatric Practice.- 3 The Theory of Negligent Malpractice.- 4 Malpractice Issues Arising during Initial Contacts with the Psychiatric Patient.- 5 The Psychiatrist's Liability for Negligent Diagnosis.- 6 The Psychiatrist's Liability for Negligence in the Process of Consent and Treatment.- II The Regulation of Psychiatric Practice by Legislative Bodies and the Courts.- 7 Civil Commitment.- 8 The Rights of the Mentally Disabled.- 9 Confidentiality in Psychiatric Practice.- III Expert Witness Roles.- 10 General Issues Regarding Psychiatric Testimony.- 11 The Psychiatric Witness and the Insanity Defense.- 12 Competency to Stand Trial.- 13 Child Custody.- 14 The Psychiatrist's Role in Evaluating Psychic Injury.- 15 Miscellaneous Expert Witness Roles in the Civil Courts.- 16 Teaching Psychiatric Residents about Legal Issues.
Electrophysiology and Ultrastructure of the Heart.
Authors: Toyomi Sano, Vinci Mizuhira, Kojiro Matsuda
Journal: Annals of Internal Medicine (1968)

a regular and necessary accompaniment of anesthesia and resuscitation. Knowing full well the difficulties of preparing a text of this nature, I am still impelled in the interest of the prospective reader to present what I think are some deficiencies. There is some strange organization. For example, hypoxia due to hypoventilation appears in the middle of the discussion on the Pharmacology of General Anesthetics; the chapter on the Recovery Room as a hodge¬ podge of items, such as oxygen therapy, endoscopy, thoracotomy drainage, and hypothermia; and the chapter on Intubation of the Tra¬ chea appears after the chapter on Resuscitation. There is also room for debate on the balance of space devoted to pertinent items. For example, there is almost as much space devoted to preoperative investigation as to the pharmacology of general anesthetic agents. There is a very short section
Enhancement of activity of 1alpha, 25-dihydroxyvitamin D3 for growth inhibition and differentiation induction of human myelomonocytic leukemia cells by tretinoin tocoferil, an alpha-tocopherol ester of all- trans retinoic acid
Authors: M Makishima, Y Kanatani, Y Yamamoto-Yamaguchi, Y Honma
Journal: Blood (1996)
Placebo-Controlled, Double-Blind, First-In-Human, Ascending Single Dose and Multiple Dose, Healthy Subject Study Of Intravenous-Administered SelG1, a Humanized Anti-P-Selectin Antibody In Development For Sickle Cell Disease
Authors: Jonathan W. Stocker, Debra Mandarino, Ziad Kawar, Richard Alvarez, David Falconer, Scott A. Rollins, Russell P. Rother
Journal: Blood (2013)
The Gamma Globulins
Authors: Fred S. Rosen, Charles A. Janeway
Journal: New England Journal of Medicine (1966)

IN 1952 Bruton reported the remarkable finding of the absence of gamma globulin from the serum of an eight-year boy who had been followed for a number of years in the pediatric section of the Walter Reed Army Hospital. The child was well up to the age of four years, when septic arthritis of the left knee developed. During the next four years of his life he had 19 episodes of pneumococcal sepsis, repeated attacks of otitis media and 2 bouts of pneumococcal pneumonia. Although these illnesses were successfully treated with antibiotics immunization of the child with polyvalent pneumococcal vaccines . . .
The Shape of Training report: fiddled facts, illogical evidence
Authors: R. Wakeford
Journal: BMJ (2015)

So the “independent” Shape of Training report1 is tainted by chicanery, unsuccessful resorting to lawyers,2 and evasions.3 To support a major thesis, it includes fiddled and illogical evidence.

A major recommendation is to register medical students a year earlier, based on information from the team’s site visits and from the Medical Schools Council. In its original evidence document (published in July 2013 but now removed from its website), the …
First Principles of Agriculture.
Authors: James Mills, Thomas Shaw
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Results of SARC 022, a phase II multicenter study of linsitinib in pediatric and adult wild-type (WT) gastrointestinal stromal tumors (GIST).
Authors: Margaret von Mehren, Suzanne George, Michael C. Heinrich, Scott Schuetze, Martin G. Belinsky, Katherine A. Janeway, Lori Rink, Kristen N. Ganjoo, Jian Qin Yu, Jeffrey T. Yap, John Joseph Wright, Annick D. Van Den Abbeele
Journal: Journal of Clinical Oncology (2014)

10507 Background: Most GISTs have activating mutations of KIT/PDGFRA, with rare cases of B-RAF/RAS mutations. 15% of GIST in adults and 85% in children are WT and commonly have high expression of IGF1R likely due to loss of succinate dehydrogenase (SDH) function. We tested the clnical benefit of linsitinib (L), an oral TKI with in vitro efficacy against IGF1R in WT GIST patients (pts). Methods: A multi-center phase II trial of L using Clopper-Pearson two-stage design was conducted by SARC. All eligible pts signed consent, were >18 yo, had KIT/ PDGFRA WT GIST, RECIST1.1 measurable disease, ECOG PS of 0-2, and adequate organ function including: fasting glucose of < 150 mg/dL, hemoglobin A1c < 7%, and a QTcF interval of < 450 msec. The trial's primary endpoint was objective response rate (ORR) and secondary endpoints were clinical benefit rate (CBR): CR, PR and SD≥9 mos, and qualitative and quantitative FDG metabolic response (MR) at 8 weeks. Results: 20 pts were accrued to stage I of the study from 11/12-4/13 (Table). Treatment with L was well tolerated. Of the toxicities reported, 8.5% were grade 3/4. 36% were possibly related to L with nausea/vomiting (7.3%), fatigue (3.6%), and elevated LFTs (3.2%) being the most common. No objective responses were seen. Qualitative partial and stable MR were seen in 6/17 (35%) respectively. As of 1/5/2014, the average days on study was 231 (range 49-318+) with 5 patients remaining on L. CBR at 9 mos was 45% and MR was seen in 2/13 (15%); PFS and OS Kaplan Meier estimates at 9 months were 52% and 80% respectively. Correlative studies of SDHB immunohistochemistry and mutational testing, serum levels of insulin, IGF1R, its ligands and inhibitors at baseline, week 2, 4 and 8 on therapy will be presented. Conclusions: L is well tolerated in patients with WT GIST. While the CBR with L was 45% and PFS at 9 mos was 52%, no objective responses have been observed. Rapid accrual to this study demonstrates clinical studies in selected subtypes of GIST are feasible. Clinical trial information: NCT01560260. Female 12 Male 8 Age 18-62, average 41 Performance status 0/1/2 12/7/1 Primary site Stomach (gastroesophageal) 16 (1) Small bowel 2 Peritoneum 1 Metastatic sites Liver 17 Peritoneum 11 Lymph nodes 4 Prior therapies 1-7, median 3
CVP alternating with fludarabine (CVP/F) chemotherapy prior to idiotype vaccination for follicular lymphoma (FL)
Authors: W. Z. Ai, F. J. Hsu, J. M. Timmerman, D. Czerwinski, B. Taidi, R. Levy, S. Horning
Journal: Journal of Clinical Oncology (2007)

8065 Background: Reducing the tumor burden prior to vaccination facilitates an effective immune response (IR) against the idiotype in FL. In this context, we evaluated the efficacy and toxicity of a novel cytoreductive regimen, CVP/F. Methods: Newly diagnosed, advanced stage FL patients (pt) were treated with CVP (cyclophosphamide 400 mg/m 2 PO d1–5, vincristine 2 mg d 1, prednisone 100 mg/m 2 d1–5) alternating with F (25 mg/m 2 IV d1–5) every 21 days for 2 cycles beyond best response (maximum 8). Pt judged to be cytoreduced adequately were vaccinated monthly × 5 with idiotype protein made from their FL. Results: Among 34 enrolled pt, median age was 45 years (yr), and FLIPI scores were: 18% low, 71% intermediate and 12% high. 38% pt had grade 1 and 62% had grade 2 FL. There were no toxic deaths or opportunistic infections. With 233 cycles (117 CVP and 116 F) given to 33 evaluable pt, neutropenic fever occurred in 7 cycles (3%). 20 cycles (17%) of CVP and 29 cycles (25%) of F were dose reduced for leukopenia. 18 pt (53%) achieved a CR (16) or CRu (2), and 13 pt (38%) had a PR. 22 pt (65%) treated with CVP/F proceeded to vaccination; 10 additional pt (29%) were vaccinated after secondary chemotherapy was given for further cytoreduction. At median follow-up of 11.2 yr, 15-yr overall survival (OS) was 85%. Two of 5 deaths occurred without lymphoma progression. TTF (time to treatment failure = second treatment, relapse, death) at 11 yr was 38%. Anti-idiotype antibody and T cell IR were seen in 44% and 31% pt, respectively. There were no differences in TTF or OS according to IR. Conclusions: CVP/ F was effective in advanced FL, comparing favorably with our historical experience with CVP in terms of CR rate, proportion proceeding to vaccination, TTF and OS after vaccination. This favorable outcome may have been due to the novel alternating CVP/F cytoreductive regimen, idiotype vaccination or both. The idiotype vaccine is now being tested in phase III trials. The CVP/F regimen also warrants further evaluation. No significant financial relationships to disclose.
Dysplastic Nevi
Authors: Jean Marie Naeyaert, Lieve Brochez
Journal: New England Journal of Medicine (2003)

A 26-year-old man comes to establish primary care. Physical examination reveals multiple moles on his body, which he describes as "funny-looking." There is no family history of melanoma. He thinks that one of his two brothers (15 years of age) and his father have the same kind of moles. How should this case be managed?
Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both
Authors: Brian A. Ference, Faisal Majeed, Raju Penumetcha, John M. Flack, Robert D. Brook
Journal: Journal of the American College of Cardiology (2015)